TABLE 4.
Diagnostic accuracy of nasal nitric oxide (nNO)
| nNO <77 nL·min−1 | nNO <77 nL·min−1 and WES | |||
| ≤5 years | >5 years | All | ||
| All subjects, including unresolved diagnosis (n=48) | ||||
| Sensitivity (95% CI) | 100 (47.8–100) | 100 (87.2–100) | 100 (89.1–100) | 93.8 (79.2–99.2) |
| Specificity (95% CI) | 33.3 (4.3–77.7) | 66.7 (22.3–95.7) | 50.0 (21.1–78.9) | 100 (73.5–100) |
| ROC area (95% CI) | 0.67 (0.46–0.87) | 0.83 (0.63–1.00) | 0.75 (0.60–0.90) | 0.97 (0.93–1.0) |
| Subjects with unresolved diagnosis excluded (n=40) | ||||
| Sensitivity (95% CI) | 100 (47.8–100) | 100 (87.2–100) | 100 (89.1–100) | 93.8 (79.2–99.2) |
| Specificity (95% CI) | 50.0 (6.8–93.2) | 100 (39.8–100) | 75 (34.9–96.8) | 100 (63.1–100) |
| ROC area (95% CI) | 0.75 (0.47–1.0) | 1.0 | 0.88 (0.72–1.0) | 0.97 (0.93–1.0) |
WES: untargeted whole-exome sequencing; ROC: receive operating characteristic.